Latest news with #Dosage
&w=3840&q=100)

Business Standard
3 days ago
- Business
- Business Standard
Laurus up for 9th straight day, soars 23% in 1 month. What's driving stock?
Laurus Labs share price: Shares of Laurus Labs continued at their northward movement, hitting a new high of ₹754.15, gaining 1 per cent on the BSE in Wednesday's intra-day trade in otherwise a weak market. The BSE Sensex was down 0.2 per cent at 83,534 at 11:02 AM. The stock of the pharmaceutical company is quoting higher for the ninth straight trading day, surging 17 per cent from level of Rs 645.85 on June 19, 2025. In the past one month, Laurus has outperformed the market and rallied 23 per cent, as compared to 2.7 per cent rise in the BSE Sensex. It has zoomed 93 per cent from its 52-week low of ₹390.30 on August 8, 2024. Laurus Labs FY25 performance, outlook After 3 years of muted earnings, Laurus Labs reported a healthy performance in FY25 with profit more than doubling. Improving asset utilisation driven by project execution in the contract development and manufacturing organisation (CDMO) Operations segment and new launches in the FDF (Finished Dosage Forms), Laurus is expected to report a steady growth in future. Laurus is well-positioned to continue evolving as a diversified CDMO and CMO leader, underpinned by a strong pipeline, enabling technologies, and commercial excellence. The management anticipates operating margins will improve further, supported by continued enhancements in utilization rates and product mix optimisation. Looking ahead, Laurus, in its FY25 annual report, said the company is committed to scaling its global CDMO footprint through continuous capacity expansion and technology investments while advancing into high-value specialty service capabilities such as biologics and gene therapy. Additionally, the company is leveraging automation and AI-driven process optimisation to enhance efficiency and compliance. With a strong foundation and a robust pipeline, the management said the company is well-positioned to capture growth opportunities and reinforce its position as a trusted global CDMO partner. ALSO READ | CARE Ratings revised outlook to stable from negative Revision in the outlook of the long-term rating for bank facilities of Laurus reflects the company's improved performance in FY25, marked by growth in total operating income (TOI), uptick in profitability margins, and strengthening debt coverage indicators. The stable outlook remains supported by anticipated scale-up of the CDMO segment in FY26, which is expected to contribute meaningfully to revenue growth and margin expansion, aided by better capacity utilisation and operational execution. Laurus has 11 manufacturing sites, of which, nine are in Vizag and two in Bangalore. This apart, the company has two Research and Development (R&D) facilities. The company's six manufacturing facilities are approved by the USFDA. Some sites are also approved by other regulatory authorities such as ANVISA Brazil, and WHO Geneva among others. The company has eight manufacturing units for APIs, one for FDF, seven inclusive units for CDMO, and two for bio-ingredients. CareEdge Ratings expects that with improved execution and a higher anticipated contribution from the CDMO segment, the company's margins will expand further by ~150-200 basis points in the coming years. This margin improvement is likely to be supported by enhanced operating leverage, increased focus on value added offerings, and more efficient capacity utilisation within the CDMO business. Going forward, the ratings agency expects that the company's capital structure is expected to strengthen further, supported by improved operational performance and enhanced cash flow generation. Considering cash accruals generated by the company in the recent past and estimated accruals, it is expected that the company would be able to meet its debt obligations comfortably after meeting its capex and increased working capital requirements, CareEdge Ratings said in its rationale dated July 1, 2025.
&w=3840&q=100)

Business Standard
5 days ago
- Business
- Business Standard
Laurus Labs nears record high after 4 years, zooms 84% from 52-week low
Laurus Labs share price Shares of Laurus Labs hit a multi-year high of ₹717.40, gaining 2 per cent on the BSE in Monday's intra-day trade on expectations of healthy earnings. Thus far in the month of June 2025, the stock has outperformed the market by surging 18 per cent, as compared to 3 per cent rise in the BSE Sensex. The stock price of the pharmaceutical company was trading close to its record high level of ₹723.55, which it touched on August 12, 2021. It has zoomed 83 per cent from its 52-week low of ₹390.30 on August 8, 2024. CATCH STOCK MARKET UPDATES TODAY LIVE Laurus Labs FY25 performance After 3 years of muted earnings, Laurus Labs reported a healthy performance in FY25 with the profit more-than-doubling at ₹358 crore. Improving asset utilization driven by project execution in the Contract Development and Manufacturing (CDMO) Operations segment and new launches in the FDF (Finished Dosage Forms), Laurus is expected to report a steady growth in future. In FY25, Laurus reported revenues of ₹5,554 crore (+10 per cent YoY growth), reflecting robust demand for CDMO offerings despite external challenges. Gross margins were maintained at a healthy 55.4 per cent, supported by a favourable product mix. EBITDA of ₹1,115 crore (+40 per cent YoY growth) resulted in a margin of 20.1 per cent, in line with outlook, and the management see a clear pathway for further margin expansion as the company continue delivering on mid-late phase projects, ramping up new assets, and better asset utilisation. Meanwhile, throughout FY25, the company successfully completed over 160 quality audits by regulatory agencies and customers- an increase of 20 per cent over the previous year - with no critical findings. The company also received Establishment Inspection Reports for its Unit 4 API facility in Visakhapatnam. Laurus is well-positioned to continue evolving as a diversified CDMO and CMO leader, underpinned by a strong pipeline, enabling technologies, and commercial excellence. The management anticipates operating margins will improve further, supported by continued enhancements in utilization rates and product mix optimisation. Laurus Labs - Outlook for FY26 and beyond Looking ahead, Laurus in its FY25 annual report said the company is committed to scaling its global CDMO footprint through continuous capacity expansion and technology investments while advancing into high-value specialty service capabilities such as biologics and gene therapy. Additionally, the company is leveraging automation and AI-driven process optimisation to enhance efficiency and compliance. With a strong foundation and a robust pipeline, the management said the company is well-positioned to capture growth opportunities and reinforce its position as a trusted global CDMO partner. India's CDMO market is expected to double by 2029, growing from $22.51 billion in 2024 to $44.63 billion at a compounded annual growth rate (CAGR) of 14.67 per cent. This growth will be driven by India's expanding role in small molecule manufacturing and the increasing demand for biologics. Looking ahead, while pricing pressures persist across generic markets, the broader outlook for the company's Generic API division remains positive. This is supported by planned capacity expansions to address current constraints, particularly in the ARV API space. A strong order book is expected to translate into sales, contributing to revenue growth, Laurus said. Meanwhile, Laurus anticipates growth in its Generic FDF division, driven by continued commercial execution on the CMO partnerships supporting portfolio diversification, ramp up in the non-ARV portfolio especially approvals within North America market. Continued focus on cost efficiency and operational excellence will help navigate pricing pressures, the company said. About Laurus Labs Laurus Labs is a research-driven, integrated pharmaceutical company with a robust presence across four core business portfolios: Contract Development and Manufacturing (CDMO), Generics Finished Dosage Forms (FDF), Active Pharmaceutical Ingredients (APIs), and Biotechnology. CDMO division provides drug development including human health and manufacturing services to global pharma, crop science, animal health, speciality ingredients and biotech firms, with facilities in Hyderabad and Visakhapatnam. Key markets include the US, EU and Japan. With the largest Hi-Potent API capabilities in India, Laurus is world's leading third-party API supplier for antiretrovirals. The company's portfolio spans ARV, oncology, steroids, hormones and cardiovascular APIs, supplied to the top global generic pharmaceutical companies.